Printer Friendly

TRINITY BIOTECH RELEASES HIV TEST TRIAL RESULTS FROM INSTITUTE OF INFECTIOUS DISEASES - ITALY

 DUBLIN, Ireland, Jan. 11 /PRNewswire/ -- Trinity Biotech (NASDAQ: HIVSY) announced results of evaluation of its SeroCard HIV-1 and HIV-1/2 by the Institute of Infectious Diseases at the University of Turin, Italy. The study used 128 subjects, including 40 confirmed HIV-1 and 5 confirmed "pure" HIV-2 patients.
 According to the Institute's written report, there were no false positives or false negatives with either test. In addition, the 5 "pure" HIV-2 patients tested positive on the HIV-1/2 test and negative on the HIV-1 test.
 The report commented, "The kits evaluated have shown their validity and reliability. They are highly sensitive and specific and show rapid results...do not require more than 7 minutes to be completed and read...both...can be...useful in situations which require a short response time (first aid stations, emergency surgery, infectious disease wards, drug user centres, etc.)."
 Trinity Biotech is an Ireland-based diagnostics company dedicated to the development of rapid, on-site, saliva tests for HIV and other sexually-transmitted diseases.
 -0- 1/11/94
 /CONTACT: Imelda Greene (Ireland), 011-353-1-29-55-111, or Michael Hubbard (United States), 503-227-0643, both of Trinity Biotech/
 (HIVSY)


CO: Trinity Biotech ST: IN: MTC SU:

RB-IC -- SE002 -- 0871 01/11/94 09:25 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1994
Words:200
Previous Article:BELL ATLANTIC CONDUCTS BID PROCESS FOR ALADDIN
Next Article:ARCADIAN PARTNERS, L.P. SIGNS AGREEMENT TO SELL LAKE CHARLES, LA., AMMONIA PLANT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters